Nexavar for desmoid tumor – pro
There is not sufficient support in the medical literature. In a retrospective cohort, the use of sorafenib revealed a slightly higher response rate (25%) compared to imatinib and a disease stabilization rate of 70%; however, no prospective data is available yet. Currently, sorafenib is being tested in a phase III, randomized, double-blind, placebo-controlled setting in the USA (NCT02066181). A randomized trial (DESMOPAZ) evaluating pazopanib versus chemotherapy with methotrexate plus vinblastine is ongoing within the French Sarcoma Group (NCT01876082).
NCCN in its section on Desmoid Tumors does list sorafenib but the name of this sections is: “Agents with activity” and NCCN does not appear to actually recommend sorafenib. In any case, it does not appear to indicate its use for second line therapy. It references the Gounder et al paper for this listing.
Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011; 17:4082.
Gounder MM, Lefkowitz RA, Keohan ML, D’Adamo DR, Hameed M, Antonescu CR, Singer S, Stout K, Ahn L, Maki RG: Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011;17:4082-4090.
NCCN, Soft Tissue Sarcoma SARC-F, 2017.